[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"barrett-oesophagitis-with-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:barrett-oesophagitis-with-dysplasia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100496563","phase-2-oral-bevacizumab-800cw-and-cetuximab-800cw-administration-to-detect-early-esophageal-adenocarcinomas-100496563",false,"NCT05745857","Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas","A Phase 2 Intervention Study: Detection of Early Esophageal Neoplastic Lesions by Quantified Fluorescence Molecular Endoscopy Using Oral and Topical Administration of Bevacizumab-800CW and Cetuximab-800CW","SLURP","Inclusion Criteria:\n\n* BE patients without dysplasia and with suspected\u002Fdiagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and\u002For therapeutic endoscopy\n* Written informed consent is obtained\n\nExclusion Criteria:\n\n* Patients under the age of eighteen.\n* Submucosal and invasive EAC, also defined as EAC with tumor, node and metastasis (TNM)-classification other than T1.\n* Previous radiation therapy for esophageal cancer\n* Known immunoglobulin allergy\n* Previous chemotherapy, immunotherapy or related surgery\n* Prior bevacizumab or cetuximab treatment\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent\n* Pregnancy or breast feeding.","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.",[27,28,29],"Barrett's Esophagus Without Dysplasia","Barrett Oesophagitis With Dysplasia","Esophageal Adenocarcinoma",[31,32,33,34],"Fluorescence molecular endoscopy","Spectroscopy","Barrett's esophagus","Esophageal adenocarcinoma","RECRUITING","2026-04-07",{"date":38,"type":39},"2026-04-13","ACTUAL",{"date":41,"type":39},"2023-09-15",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"University Medical Center Groningen","OTHER"]